Trump delays pharmaceutical tariffs

After threatening triple-digit pharmaceutical tariffs that would have become effective Oct. 1, the Trump administration paused its plan as it tries to negotiate agreements with large pharmaceutical companies that want to avoid higher tariffs on their name-brand products. The administration announced a deal with Pfizer on Sept. 30. The New York-based company will invest $70 billion to increase its U.S. manufacturing capacity and participate in a direct purchasing platform called “TrumpRx.gov,” where it will offer some discounts on its products. Pfizer, in exchange, will receive a three-year pause on the forthcoming pharmaceutical tariffs. The American Hospital Association has urged the administration to maintain tariff exceptions, particularly for products already experiencing shortages and for countries producing a significant portion of the U.S. pharmaceuticals. (Politico article, 10/1/25)